Halia Therapeutics Announces First Participant Dosed in Phase 1 Clinical Study of HT-6184, a Novel NEK7/NLRP3 Inhibitor
SALT LAKE CITY, June 15, 2022 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biotechnology company discovering and developing small molecule therapeutics to treat inflammator…
